NICE has announced that the immunotherapy nivolumab will now be made available on the Cancer Drugs Fund for treating locally advanced or metastatic squamous and non-squamous non-small-cell lung cancers after prior chemotherapy.
Browsing: Taxonomy > Immunotherapy
Listen to this podcast to discover more about CheckMate-153 study, data from which was presented at this years 2017 ESMO Congress (8–12th September, Madrid, Spain).
One of Britain’s biggest privately owned biotech companies is set to secure additional funding which could propel its progress in developing novel immunotherapies.
Discover more about idiopathic thrombocytopenic purpura in this case report from Immunotherapy.
Results from two international clinical trials yield promising results for halting the mestatise of melanoma, yield novel treatment options for melanoma and may help stop this form of cancer metastizing.
A recent clinical trial presents new data indicating durvalumab improves progression-free survival in patients with stage III non-small-cell lung cancer (NSCLC).
Researchers at Massachusetts General Hospital (MA, USA) report the first response to chimeric antigen receptor (CAR) T-cells in a central nervous system lymphoma.
A novel combination therapy has produced cancer vaccinations in mice involved in a proof-of-concept study.
Research into the PD-L1 pathway has discovered a novel protein known as CMTM6, which binds to PD-L1 on T cell surfaces and enhances PD-L1’s ability to inhibit T cell immune responses. The findings may offer a novel immunotherapy target for many types of cancer.
A novel CRISPR-Cas9 screening method has revealed new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising class of cancer immunotherapeutics.